CAR-TIM3 NK-92 cells

CAR-TIM3 NK-92 cells are genetically engineered human natural killer (NK) cells, based on the NK-92 cell line, that have been modified to express a chimeric antigen receptor (CAR) targeting TIM3 (T cell immunoglobulin and mucin-domain containing-3). The CAR construct incorporates a TIM3-specific scFv linked with CD28, 4-1BB, and CD3ζ intracellular signaling domains, designed for enhanced activation and antitumor activity. These cells selectively recognize and kill TIM3-expressing targets, notably leukemic stem cells (LSCs) in acute myeloid leukemia (AML), and show potent cytotoxicity with minimal effects on normal hematopoietic progenitors. CAR-TIM3 NK-92 cells have demonstrated efficacy in vitro and in vivo against AML, reducing leukemic burden in mouse models. This approach leverages the “off-the-shelf” potential of NK-92 cells, the only NK cell line approved for clinical trials, and offers a potentially safer profile than CAR-T therapy while directly targeting therapy-resistant AML cells and alleviating NK cell exhaustion[2][3].

Other names

anti-TIM3 CAR NK-92 cellsanti-TIM-3 CAR NK-92 cellsanti-TIM 3 CAR NK-92 cellsTIM3 CAR-NK-92TIM-3 CAR-NK-92TIM 3 CAR-NK-92CAR-TIM3 NK cellsCAR-TIM-3 NK cellsCAR-TIM 3 NK cells